✦ LIBER ✦

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide

✍ Scribed by DeKoven, Mitch; Lee, Won Chan; Bouchard, Jonathan; Massoudi, Marjan; Langer, Jakob

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Real World Outcomes in Type 2 Diabetes:

✍ Dekoven, M.; Lee, W.C.; Bouchard, J.R.; Massoudi, M.; Langer, J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PDB33 The Associated Costs of Treating T

✍ J. Langer; J.R. Bouchard 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Evaluating the Long-Term Cost-Effectiven

✍ William J. Valentine; Andrew J. Palmer; Morten Lammert; Jakob Langer; Michael Br 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 505 KB

PRS21 Cost-Effectiveness of Budesonide/F

✍ Hedegaard, M.; Janson, C.; Lisspers, K.; Ställberg, B.; Johansson, G.; Jörgensen 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost Effectiveness Of Budesonide/Formote

✍ Hedegaard, M.; Janson, C.; Lisspers, K.; Ställberg, B.; Johansson, G.; Jørgensen 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

Cost Effectiveness of Rosuvastatin in Tr

✍ Paul S.J. Miller; Dean G. Smith; Peter Jones 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 226 KB